Despite continual progress in the treatment and management of acute myeloid leukemia (AML), relapse rates following allogeneic stem cell transplantation remain unacceptably high and a major cause of death. There have been various attempts to improve outcomes in this setting of AML which need to be integrated on a case-by-case basis.This archived series, led by expert faculty, will provide guidance and practical strategies to safely implement recent progress in addressing post-transplantation rel...

Talking Multiple Myeloma highlights recent advances in the initial management of multiple myeloma. Through patient cases and scenarios, the expert faculty presenters will guide the integration of new evidence into clinical treatment paradigms of newly diagnosed multiple myeloma.

This is the first of four modules associated with this activity.Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.This certified AMA activity will highli...

This is the second of four modules associated with this activity.Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.This certified AMA activity will highl...

This is the third of four modules associated with this activity.Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.This certified AMA activity will highli...

This is the fourth of four modules associated with this activity.Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.This certified AMA activity will highl...

This online course is a recording of the live Internal Medicine Medical Grand Rounds presentation on January 12, 2022.Learners should not claim credit for both the live session and this online course; review your transcript to determine if you received credit for the live session before taking this course. Speaker of this presentation cannot claim credit.Course Structure:1.  Review CME Front Matter, and review speaker/planning member's disclosure information located i...